Over the last 20 yearsTherakos has attempted to take traditional medicine to a new level. We have done this by seeking new ways of managing disease and collaborating with clinicians and researchers.

We are customer-focused. Our aim is to exceed the expectations of our customers - the worldwide medical community and the patients to whom we are ultimately responsible.

Together we saw the possibilities that existed within photopheresis and the field of immune cell therapy. Now we are bringing it to the people who need it the most.

We are science driven. Today we are indicated for cutaneous T-cell lymphoma. Tomorrow the possibilities are endless.

Our engineers, clinicians, and biological researchers are committed to the discovery and commercialization of new applications, technologies, and therapeutic improvements. We strive to save lives. We are committed to saving lives by treating life-threatening diseases and by preserving the quality of lives affected by chronic, often disabling diseases.

Understanding Photopheresis
Extracorporeal photopheresis (ECP) therapy is performed using the THERAKOS UVAR® XTS™ instrument. After first removing whole blood from the patient, the UVAR® XTS™ centrifuges the blood to separate red blood cells (RBCs) from the leukocyte-containing buffy coat cells. The RBCs and plasma are then immediately returned to the patient. The buffy coat cells remain in the UVAR® XTS™ machine, where they are treated with methoxsalen and irradiated with UVA (ultraviolet-A) light, which photoactivates the drug. The photoactivated buffy coat cells are then returned to the patient.

Click here to close this window
and return to the Dermatology Update Sponsors Page.